Anti-D human immunoglobulin: new preparation. Important in young Rh D (-) women.
(1) Nat/eaD degrees , a product based on anti-D human immunoglobulin, is marketed in France for the prevention of alloimmunisation to Rhesus D antigen in obstetrics and after mismatched transfusion.  (2) Anti-D human immunoglobulin has been in clinical use for more than 30 years. Its assessment is based more on experience than on well-designed comparative trials.  (3) A meta-analysis of 6 trials involving more than 10,000 women demonstrated the efficacy of anti-D human immunoglobulin as prophylaxis after delivery of a Rhesus D-positive infant to a Rhesus D-negative woman.  However, the optimal dose regimen and route of administration remain unclear.  (4) Some data favour the use of anti-D human immunoglobulin after abortion, as it appears to reduce immunisation rates from about 3-4% to 0.4%.  (5) Anti-D human immunoglobulin is likely to be effective antenatally in circumstances or procedures carrying a risk of maternal exposure to fetal red cells, although this has not been proved in comparative trials.  (6) Efficacy of anti-D human immunoglobulin in anti-D alloimmunisation after mismatched transfusions has been described only in small clinical pharmacology studies in healthy volunteers.  (7) The manufacturing process does not rule out a theoretical risk of nude virus or prion transmission, although no cases have been reported with NateaD degrees .
D004899:Erythroblastosis, Fetal / Q000517:prevention & control; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D012203:Rh Isoimmunization / Q000188:drug therapy / Q000517:prevention & control; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use; D065227:Transfusion Reaction
D018029:Rho(D) Immune Globulin